The article presents the results of an open comparative randomized clinical study on the assessment of the reactogenicity, safety and immunogenicity of the domestic vaccine "EntseVir®" with reduced antigenic load in immunization of children aged 3 to 17 years on the schedule for 0-60 days. The vaccine is characterized by the low reactogenicity, high safety profile and immunogenicity. On main indices, it is not inferior to foreign vaccine «FSME-Immun Inject / Junior».
Relevanc. Measles, mumps and rubella, despite many years of vaccination, retain their epidemiological and social significance at the present time. The aim of the work is to study the safety and immunogenicity. Of the vaccine for the prevention of measles, rubella and mumps Vactrivir® in children's immunization. Materials and methods. The safety and immunogenicity of the vaccine was studied in a simple multicenter blind comparative randomized clinical trial involving children aged 12 months and 6 years. Results. The Vactrivir® vaccine is characterized by low reactogenicity, a high safety and immunogenicity profile and is comparable in terms of indicators to the foreign Priorix® vaccine, which has been used in the Russian Federation for specific prevention of measles, rubella and mumps since 2018.
Aim is comparative evaluation of the safety and immunogenicity of inactivated poliomyelitis vaccine (IPV) «Bilthoven Biologicals B.V.» (Netherlands) and «Imovax Polio» (France) with subcutaneous and intramuscular modes of administration. Materials and methods. In a doubleblind, comparative clinical randomized multicenter study, 120 children at the age of 3 months participated as volunteers. They were divided into 4 groups: 1 and 2 groups were given IPV intramuscular (group 1) and subcutaneous (group 2) mode of administration, children of groups 3 and 4 were given the vaccine «Imovax Polio». Results. IPV is characterized by a high safety profile and immunogenicity both in subcutaneous and intramuscular modes of administration and it is comparable in its characteristics with the vaccine «Imovax Polio». Conclusion. Vaccine IPV (Netherlands) is recommended for registration in the territory of the Russian Federation and its further using in the National Vaccination Schedule.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.